预测前列腺特异性抗原查测试后前列腺癌死亡率的长期风险:预后模型开发和外部验证
Patrick Lewicki1, Ralph Jiang2, Archana Radhakrishnan3
1Department of Urology, University of Michigan, Ann Arbor, Michigan (P.L., T.M.M.).
Annals of internal medicine
|January 12, 2026
概括
开发并验证了一种新的前列腺癌死亡风险模型. 该模型改善了前列腺特异性抗原 (PSA) 测试结果的解释,用于预测前列腺癌特异性死亡率 (PCSM).
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 公共卫生 公共卫生
背景情况:
- 目前使用前列腺特异性抗原 (PSA) 测试进行前列腺癌 (PCa) 查,缺乏预测时间到事件结果或考虑患者预期寿命的模型.
- 现有的PCa预测模型不能充分解决随时间推移的死亡风险细微差别.
研究的目的:
- 开发一种新的预后模型,在PSA测试后预测前列腺癌特异性死亡率 (PCSM) 风险.
- 通过外部验证这个新模型,并将其性能与现有的风险预测工具进行比较.
- 在长期死亡风险的背景下,提高PSA测试结果的解释.
主要方法:
- 预后模型开发使用了前列腺,肺,结肠直肠和卵巢 (PLCO) 癌症查试验PCa查组的数据.
- 外部验证是在接受PSA测试的大量退伍军人事务 (VA) 队列患者进行的.
- 关键预测因素包括PSA水平,PCa家族史,种族,年龄,BMI,吸烟状况和并发症 (高血压,糖尿病,中风).
主要成果:
- 这种新型模型在开发和验证队列中表现出优异的性能,与先前验证的前列腺活检风险模型 (PBCG) 相比.
- 在发展队列中,29.5年接受器运行特征曲线 (AUC) 下的面积为新模型的0.666,而PBCG的0.643 (P < 0.001).
- 在外部验证队列中,20年后的AUC为新模型的0.776,而PBCG的0.749 (P = 0.031).
结论:
- 通过使用长期临床试验和国家队列数据,成功开发并验证了PCSM的新预后模型.
- 与现有的工具相比,该模型在预测PCa特定死亡风险方面提供了更高的准确性.
- 经过验证的模型可以帮助临床医生更好地解释PSA测试结果,并评估个体患者的风险.
相关概念视频
01:21Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
01:20Actuarial Approach
284
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
284
01:20Comparing the Survival Analysis of Two or More Groups
548
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
548